Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Authors
Keywords
-
Journal
DRUGS
Volume 81, Issue 11, Pages 1331-1342
Publisher
Springer Science and Business Media LLC
Online
2021-07-22
DOI
10.1007/s40265-021-01558-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis
- (2021) Rudolph M Navari et al. Future Oncology
- Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life
- (2020) Meinolf Karthaus et al. Future Oncology
- Antiemetics: ASCO Guideline Update
- (2020) Paul J. Hesketh et al. JOURNAL OF CLINICAL ONCOLOGY
- Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
- (2019) Lee Schwartzberg et al. Cancer Medicine
- Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting
- (2019) Sang Hee Park et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
- (2019) Marc Botteman et al. SUPPORTIVE CARE IN CANCER
- PCN54 ECONOMIC EVALUATION OF PALONOSETRON/ NETUPITANT FOR THE TREATMENT OF CHEMOTHERAPY-RELATED NAUSEA AND VOMITING
- (2019) R. Rubio Ponce et al. VALUE IN HEALTH
- PCN206 NETUPITANT AND PALONOSETRON (NEPA), IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SINGAPORE
- (2019) S.W. Lim et al. VALUE IN HEALTH
- Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
- (2019) Lee Schwartzberg et al. ONCOLOGIST
- Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy
- (2018) L Schwartzberg et al. ANNALS OF ONCOLOGY
- Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy
- (2018) Snežana M. Bošnjak et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting
- (2018) James Gilmore et al. JOURNAL OF CLINICAL PHARMACOLOGY
- PCN174 - NEPA, AN ORAL FIXED COMBINATION OF NETUPITANT AND PALONOSETRON, IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN GERMANY AND GREECE
- (2018) F. Bourhis et al. VALUE IN HEALTH
- Phase III study of palonosetron (PALO) given as 30-min IV infusion (IV inf) versus 30-sec IV bolus (IV bol) for prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC).
- (2017) Meinolf Karthaus et al. JOURNAL OF CLINICAL ONCOLOGY
- Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
- (2017) Paul J. Hesketh et al. SUPPORTIVE CARE IN CANCER
- Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients
- (2017) Matti Aapro et al. Journal of Geriatric Oncology
- Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program
- (2016) Matti Aapro et al. ONCOLOGIST
- NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
- (2016) Matti Aapro et al. SUPPORTIVE CARE IN CANCER
- 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy
- (2016) Fausto Roila et al. SUPPORTIVE CARE IN CANCER
- 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy
- (2016) Jørn Herrstedt et al. SUPPORTIVE CARE IN CANCER
- Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting
- (2015) Gillian M. Keating DRUGS
- Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
- (2014) P. J. Hesketh et al. ANNALS OF ONCOLOGY
- A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
- (2014) R. J. Gralla et al. ANNALS OF ONCOLOGY
- A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
- (2014) M. Aapro et al. ANNALS OF ONCOLOGY
- Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells
- (2014) Ajit G. Thomas et al. EXPERIMENTAL BRAIN RESEARCH
- Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives
- (2013) Selma Calcagnile et al. SUPPORTIVE CARE IN CANCER
- Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects
- (2012) Marigo Stathis et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo
- (2010) C. Rojas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor
- (2009) Camilo Rojas et al. ANESTHESIA AND ANALGESIA
- Palonosetron
- (2009) Lily P.H. Yang et al. DRUGS
- Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function
- (2009) Camilo Rojas et al. EUROPEAN JOURNAL OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More